Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 118   

Articles published

JNJ 102.67 +1.45 (1.43%)
price chart
Johnson & Johnson Plans Ebola Vaccine Testing
Johnson & Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus.
Why Johnson & Johnson (JNJ) Stock Is Higher Today  TheStreet.com
Related articles »  
Johnson & Johnson to Begin Testing Ebola Vaccine in January
Johnson & Johnson said it would begin testing an Ebola-virus vaccine in humans in January and could have 250,000 doses available in May, if health authorities deem it safe and promising enough to distribute more broadly.
Ebola roundup: J&J invests $200M in R&D, Glaxo says vaccine will ...  FierceVaccines
Related articles »  
Ebola: Johnson & Johnson to start vaccine trials in January
Johnson & Johnson is to start testing its Ebola vaccine candidate in January after the World Health Organisation (WHO) and world leaders asked it and other companies to accelerate their research programmes.
TMC confirms Johnson & Johnson incubator
Johnson & Johnson has similar incubators in San Diego, San Francisco and Boston. And although Houston has long been known as a medical hub, with nearly $1 billion worth of research at the Texas Medical Center annually, something's been missing.
Johnson & Johnson Opens New J-Labs Incubator in Texas  Genetic Engineering & Biotechnology News
J&J heads to Texas with its R&D farm system, scouting for biotech ...  FierceBiotech
Related articles »  
Johnson & Johnson to Buy Biotech Company Alios BioPharma
The deal has been approved by the boards of both companies, and is the first acquisition in some time for Johnson & Johnson, which has been more focused on selling assets than buying them this year. In March, Johnson & Johnson sold its K-Y brand of ...
Johnson & Johnson to buy private drug developer for $1.75 billion  Reuters
What Johnson & Johnson's Alios Acquisition Means for Gilead Sciences  Barron's (blog)
Related articles »  
Johnson & Johnson accelerates Ebola vaccine testing amid heightened anxiety
"We are urgently working to provide our vaccine expertise, production capabilities, our people and resources to address the Ebola crisis," said Alex Gorsky, Chairman and CEO of Johnson & Johnson." Our innovation model enables us to quickly mobilize our ...
Is Johnson & Johnson's Worst Nightmare Becoming Reality?
Johnson & Johnson (NYSE: JNJ ) has been one of the few top healthcare companies to post strong growth within its pharmaceutical segment this year.
Related articles »  
Johnson & Johnson fuel Knights' playoffs quest
GAINESVILLE - The Johnson & Johnson trademark usually means a company geared to healing and pain-reduction, but in local football circles, the names Johnson and Johnson - namely Jordan Johnson and Marcus Johnson - have become synonymous ...
Johnson & Johnson investing $200 million to develop Ebola vaccine (Video)
Johnson & Johnson (NYSE: JNJ) is developing the vaccine in partnership with Denmark-based biotechnology company Bavarian Nordic and is also licensing Bavarian's vaccine and buying new shares in the company in a potential investment of more than ...
Market Reaction To Johnson & Johnson's Earnings Is Justified
Johnson & Johnson's stock price fell sightly following its Q3 2014 earnings announcement despite the company beating consensus estimates and keeping the full year outlook the same.